AR081395A1 - Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y uso - Google Patents
Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y usoInfo
- Publication number
- AR081395A1 AR081395A1 ARP110101656A ARP110101656A AR081395A1 AR 081395 A1 AR081395 A1 AR 081395A1 AR P110101656 A ARP110101656 A AR P110101656A AR P110101656 A ARP110101656 A AR P110101656A AR 081395 A1 AR081395 A1 AR 081395A1
- Authority
- AR
- Argentina
- Prior art keywords
- lantane
- oxycarbonate
- manufacture
- methods
- carbonate hydroxide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/247—Carbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/10—Solid density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/11—Powder tap density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/12—Surface area
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/14—Pore volume
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Geology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33388710P | 2010-05-12 | 2010-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081395A1 true AR081395A1 (es) | 2012-08-29 |
Family
ID=44279001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101656A AR081395A1 (es) | 2010-05-12 | 2011-05-13 | Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y uso |
| ARP200100076A AR117804A2 (es) | 2010-05-12 | 2020-01-10 | Composiciones farmacéuticas que comprenden una cantidad efectiva de dioxicarbonato de lantano y compuestos de dioxicarbonato de lantano |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100076A AR117804A2 (es) | 2010-05-12 | 2020-01-10 | Composiciones farmacéuticas que comprenden una cantidad efectiva de dioxicarbonato de lantano y compuestos de dioxicarbonato de lantano |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8961917B2 (enExample) |
| EP (2) | EP2568989B1 (enExample) |
| JP (4) | JP5993368B2 (enExample) |
| KR (2) | KR101830456B1 (enExample) |
| CN (1) | CN103037870B (enExample) |
| AR (2) | AR081395A1 (enExample) |
| AU (1) | AU2011252983C1 (enExample) |
| BR (1) | BR112012028629B8 (enExample) |
| CA (2) | CA3224506A1 (enExample) |
| ES (1) | ES2871021T3 (enExample) |
| IL (1) | IL222824B (enExample) |
| MX (1) | MX350075B (enExample) |
| RU (1) | RU2570007C2 (enExample) |
| TW (1) | TWI446916B (enExample) |
| WO (1) | WO2011143475A1 (enExample) |
| ZA (1) | ZA201209322B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011252983C1 (en) | 2010-05-12 | 2015-02-19 | Unicycive Therapeutics, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
| CN104379739A (zh) | 2012-06-05 | 2015-02-25 | 3M创新有限公司 | 镧基微生物浓集剂 |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| CN104129810A (zh) * | 2013-05-02 | 2014-11-05 | 南京大学 | 纯单斜晶相的刺球状碳酸氧镧(La2O2CO3)三维多级结构的制备 |
| CN104592994B (zh) * | 2015-01-14 | 2018-01-02 | 惠州学院 | 一种三角枝状铕掺杂羟基碳酸镧红色荧光粉的制备方法 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| JP6093829B1 (ja) * | 2015-10-02 | 2017-03-08 | バイエル薬品株式会社 | ランタン化合物を含む医薬組成物 |
| CN105749892B (zh) * | 2016-05-16 | 2018-02-02 | 哈尔滨工业大学 | 一种针对水体除磷的海胆状微球碳酸氧镧吸附剂的制备方法 |
| WO2017221497A1 (ja) * | 2016-06-24 | 2017-12-28 | 日本碍子株式会社 | 層状複水酸化物を含む機能層及び複合材料 |
| CN107188215A (zh) * | 2017-05-24 | 2017-09-22 | 中国北方稀土（集团）高科技股份有限公司 | 碳酸稀土连续沉淀生产过程中自动调节反应终点的方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RU2657755C1 (ru) * | 2017-07-10 | 2018-06-15 | Александр Александрович Кролевец | Способ получения нанокапсул солей лантаноидов в каррагинане |
| US11865509B2 (en) | 2018-01-04 | 2024-01-09 | Asahi Kasei Kabushiki Kaisha | Porous molding |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| WO2020012870A1 (ja) | 2018-07-13 | 2020-01-16 | 富士電機株式会社 | 二酸化炭素ガスセンサ |
| WO2020040233A1 (ja) * | 2018-08-21 | 2020-02-27 | 東和薬品株式会社 | 化合物の特定形状の結晶及びその製造方法 |
| JP2020099866A (ja) * | 2018-12-21 | 2020-07-02 | 旭化成株式会社 | 多孔性成形体 |
| RU2693176C1 (ru) * | 2018-12-28 | 2019-07-01 | Общество С Ограниченной Ответственностью "Лаборатория Инновационных Технологий" | Способ получения карбонатов редкоземельных элементов |
| CN109490464A (zh) * | 2019-01-24 | 2019-03-19 | 内蒙古医科大学 | 一种基于离子色谱技术测定稀土药物中镧元素含量的方法 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN113029978A (zh) * | 2019-12-25 | 2021-06-25 | 远大生命科学(辽宁)有限公司 | 一种检测含镧试剂的磷结合能力的方法 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN113019305B (zh) * | 2021-03-03 | 2021-10-15 | 重庆三峡学院 | 多孔碱式碳酸镧磷酸盐吸附剂的制备及其应用 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CN113311100A (zh) * | 2021-05-27 | 2021-08-27 | 南京诺亚药业有限公司 | 一种碳酸镧制剂中的镧含量的测定方法 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN115487839B (zh) * | 2021-06-17 | 2024-03-26 | 中国石油化工股份有限公司 | 片状催化剂及其制备方法和应用 |
| CN116924450B (zh) * | 2022-03-29 | 2025-09-30 | 包头稀土研究院 | 用氯化稀土料液制备碱式碳酸稀土的方法 |
| CN116924449B (zh) * | 2022-03-29 | 2025-12-09 | 包头稀土研究院 | 碱式碳酸镧颗粒及其制备方法 |
| CN114749182A (zh) * | 2022-03-29 | 2022-07-15 | 中国科学院兰州化学物理研究所 | 一种用于甲烷干重整的镍-氧化镧催化剂及其制备方法 |
| MA71322A (fr) * | 2022-07-01 | 2025-04-30 | Amgmt | Forme posologique pharmaceutique administrable par voie orale comprenant du lanthane et son utilisation dans une méthode de traitement de l'hyperoxalurie |
| CN116809015A (zh) * | 2023-04-03 | 2023-09-29 | 中国市政工程中南设计研究总院有限公司 | 一种粘土-碳酸镧复合材料及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3768989A (en) | 1968-08-19 | 1973-10-30 | N Goetzinger | Process for the preparation of a rare earth oxide polishing composition |
| US3692671A (en) | 1970-10-01 | 1972-09-19 | North American Rockwell | Rare earth ion removal from waste water |
| US3922333A (en) | 1973-06-04 | 1975-11-25 | Us Air Force | Process for preparing mullite powder and fabrication of structural bodies therefrom |
| US3922331A (en) | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
| US4240048A (en) | 1978-12-15 | 1980-12-16 | E. I. Du Pont De Nemours & Co. | Nonlinear optical device |
| DE3066207D1 (en) | 1980-11-14 | 1984-02-23 | Rudolf Schanze | Concentrate containing trace elements suitable for men and animals, method for its preparation and utilization thereof |
| US4462970A (en) | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
| US4497785A (en) | 1983-11-18 | 1985-02-05 | Union Oil Company Of California | Production of rare earth compounds |
| JPS60206448A (ja) | 1984-03-29 | 1985-10-18 | Nissan Motor Co Ltd | 排ガス浄化用触媒担体 |
| JPS60226414A (ja) | 1984-04-20 | 1985-11-11 | Hitachi Ltd | ランタン・アルミナ系複合酸化物の製造法 |
| JPS614529A (ja) | 1984-06-15 | 1986-01-10 | Asahi Chem Ind Co Ltd | リン酸イオンの吸着剤 |
| AU601998B2 (en) | 1985-07-11 | 1990-09-27 | Rhone-Poulenc Specialites Chimiques | Oxygenated rare earth derivatives |
| US5782792A (en) | 1986-11-21 | 1998-07-21 | Cypress Bioscience, Inc. | Method for treatment of rheumatoid arthritis |
| US4919902A (en) | 1987-09-30 | 1990-04-24 | Allied-Signal Inc. | Catalyst for treatment of exhaust gases from internal combustion engines |
| FR2623797B2 (fr) | 1987-08-05 | 1990-05-04 | Inst Francais Du Petrole | Procede de conversion du methane en hydrocarbures superieurs |
| US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| FR2634398B1 (fr) | 1988-06-29 | 1990-09-07 | Elf Aquitaine | Procede de preparation d'un catalyseur apte a promouvoir la conversion oxydante du methane en hydrocarbures superieurs |
| GB9201857D0 (en) | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
| US5407560A (en) | 1992-03-16 | 1995-04-18 | Japan Energy Corporation | Process for manufacturing petroleum cokes and cracked oil from heavy petroleum oil |
| EP0604919A1 (en) | 1992-12-28 | 1994-07-06 | Ishihara Sangyo Kaisha, Ltd. | Deodorant |
| WO1994019286A1 (en) | 1993-02-24 | 1994-09-01 | Dudley John Mills | Treatment of swimming pool water |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| JPH0810610A (ja) | 1994-07-05 | 1996-01-16 | Ishihara Sangyo Kaisha Ltd | リン吸着剤 |
| GB9506126D0 (en) | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
| US20020183288A1 (en) | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US6376479B1 (en) | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| GB9611437D0 (en) | 1995-08-03 | 1996-08-07 | Secr Defence | Biomaterial |
| JP2843909B2 (ja) | 1996-05-27 | 1999-01-06 | 科学技術庁無機材質研究所長 | 酸化イットリウム透明焼結体の製造方法 |
| JP3081910B2 (ja) | 1997-08-07 | 2000-08-28 | 工業技術院長 | ヒ素（ｖ）イオンの除去方法 |
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US5843477A (en) | 1997-09-30 | 1998-12-01 | Bayer Corporation | Lubricants for use in tabletting |
| CA2327685C (en) | 1998-04-03 | 2008-11-18 | Bm Research A/S | Controlled release composition |
| US6197201B1 (en) | 1998-07-29 | 2001-03-06 | The Board Of Regents Of The University & Community College System Of Nevada | Process for removal and stabilization of arsenic and selenium from aqueous streams and slurries |
| US6312604B1 (en) | 1998-10-23 | 2001-11-06 | Zodiac Pool Care, Inc. | Lanthanide halide water treatment compositions and methods |
| CA2395530C (en) | 1999-12-22 | 2008-07-15 | Wisconsin Alumni Research Foundation | Calcium formate for use as a phosphorus binder and a dietary supplement |
| US6338800B1 (en) | 2000-02-22 | 2002-01-15 | Natural Chemistry, Inc. | Methods and compositions using lanthanum for removing phosphates from water |
| US6521647B2 (en) | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| GB0015745D0 (en) | 2000-06-27 | 2000-08-16 | Shire Holdings Ag | Treatment of bone diseases |
| JP3407039B2 (ja) | 2000-07-10 | 2003-05-19 | 独立行政法人産業技術総合研究所 | ヒ素汚染土壌洗浄剤並びにヒ素汚染土壌安定化剤及びこれらをを用いたヒ素汚染土壌修復方法 |
| FR2811571B1 (fr) | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
| US6403523B1 (en) | 2000-09-18 | 2002-06-11 | Union Carbide Chemicals & Plastics Technology Corporation | Catalysts for the oxidative dehydrogenation of hydrocarbons |
| FR2820134A1 (fr) | 2001-01-29 | 2002-08-02 | Rhodia Elect & Catalysis | Oxychlorure de terre rare a surface specifique elevee, ses procedes de preparation et son utilisation comme catalyseur |
| US6849609B2 (en) | 2001-04-10 | 2005-02-01 | James U. Morrison | Method and composition for controlled release acarbose formulations |
| ATE499943T1 (de) * | 2001-04-23 | 2011-03-15 | Shire Int Licensing Bv | Verwendung von lanthankarbonat zur prävention von nierensteinleiden |
| CN100408029C (zh) | 2001-09-28 | 2008-08-06 | 麦克内尔-Ppc股份有限公司 | 有镶嵌部分的组合剂型 |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| WO2003094933A2 (en) | 2002-05-08 | 2003-11-20 | Shire Holding Ag | Use of lanthanum for the treatment of hypercalcemia and bone metastasis |
| US20040161474A1 (en) | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
| US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
| CN100526219C (zh) * | 2002-08-14 | 2009-08-12 | 爱尔达纳米公司 | 稀土金属化合物、其制造方法及其使用方法 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| AU2003298800B2 (en) | 2002-12-02 | 2007-11-29 | Altairnano, Inc. | Rare earth compositions and structures for removing phosphates from water |
| JP4128906B2 (ja) * | 2003-05-15 | 2008-07-30 | 三井金属鉱業株式会社 | セリウム系研摩材及びセリウム系研摩材の製造方法 |
| US7381428B2 (en) | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
| NZ545633A (en) * | 2003-08-26 | 2009-07-31 | Shire Holdings Ag | Pharmaceutical formulation comprising lanthanum compounds |
| JP4834953B2 (ja) | 2003-10-31 | 2011-12-14 | 富士ゼロックス株式会社 | 脂肪族ポリケトン類ポリマー及び脂肪族ポリケトン類ポリマー含有組成物の製造方法 |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| JP2007511528A (ja) | 2003-11-13 | 2007-05-10 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 心肥大および心不全の処置としてのｔｒｐチャネル阻害方法 |
| CN1557982A (zh) | 2004-01-19 | 2004-12-29 | 太原理工大学 | 细化阻燃复合剂及其制备方法 |
| NZ552861A (en) | 2004-07-27 | 2010-11-26 | Shire Pharmaceuticals Inc | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate |
| JP2008516971A (ja) * | 2004-10-15 | 2008-05-22 | アルテアーナノ，インコーポレーテッド | 錠剤による負荷が軽減されるリン酸塩結合剤 |
| US20060177415A1 (en) | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| EP1698233A1 (en) | 2005-03-01 | 2006-09-06 | Bayer HealthCare AG | Reduction of digestibility of phosphorus in animal nutrition |
| EP1922746A4 (en) | 2005-08-11 | 2010-08-11 | Innovalight Inc | STABLEALLY PASSIVE NANOPARTICLES OF GROUP IV SEMICONDUCTOR, METHODS AND COMPOSITIONS THEREOF |
| EP1928349A4 (en) | 2005-08-17 | 2008-10-01 | Altairnano Inc | COMPOSITIONS AND METHODS FOR TREATING CHRONIC RENAL FAILURE AND OTHER CONDITIONS IN DOMESTIC ANIMALS |
| US20080069860A1 (en) | 2005-08-17 | 2008-03-20 | Allison Wren | Hyperphosphatemia in domestic animals: compositions and methods of treatment |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| CN101077338B (zh) * | 2006-05-24 | 2012-06-20 | 天津大学 | 纳米碳酸镧口腔崩解片及制备方法 |
| KR102004542B1 (ko) | 2009-11-06 | 2019-07-26 | 테라파워, 엘엘씨 | 핵분열 원자로에서 연료 집합체를 이동시키는 방법 및 시스템 |
| AU2011252983C1 (en) | 2010-05-12 | 2015-02-19 | Unicycive Therapeutics, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
-
2011
- 2011-05-12 AU AU2011252983A patent/AU2011252983C1/en active Active
- 2011-05-12 KR KR1020127032038A patent/KR101830456B1/ko active Active
- 2011-05-12 ES ES11721201T patent/ES2871021T3/es active Active
- 2011-05-12 JP JP2013510310A patent/JP5993368B2/ja active Active
- 2011-05-12 WO PCT/US2011/036317 patent/WO2011143475A1/en not_active Ceased
- 2011-05-12 MX MX2012013065A patent/MX350075B/es active IP Right Grant
- 2011-05-12 US US13/106,637 patent/US8961917B2/en active Active
- 2011-05-12 EP EP11721201.9A patent/EP2568989B1/en active Active
- 2011-05-12 CA CA3224506A patent/CA3224506A1/en active Pending
- 2011-05-12 CN CN201180023076.0A patent/CN103037870B/zh active Active
- 2011-05-12 KR KR1020177030161A patent/KR101940207B1/ko active Active
- 2011-05-12 TW TW100116778A patent/TWI446916B/zh active
- 2011-05-12 RU RU2012146818/05A patent/RU2570007C2/ru active
- 2011-05-12 CA CA2798081A patent/CA2798081C/en active Active
- 2011-05-12 EP EP21159393.4A patent/EP3848040A1/en active Pending
- 2011-05-12 BR BR112012028629A patent/BR112012028629B8/pt active IP Right Grant
- 2011-05-13 AR ARP110101656A patent/AR081395A1/es active IP Right Grant
-
2012
- 2012-11-01 IL IL222824A patent/IL222824B/en active IP Right Grant
- 2012-12-10 ZA ZA2012/09322A patent/ZA201209322B/en unknown
-
2013
- 2013-12-12 US US14/104,663 patent/US10350240B2/en active Active
-
2016
- 2016-04-07 JP JP2016077533A patent/JP6397845B2/ja active Active
-
2018
- 2018-05-22 JP JP2018097513A patent/JP6938425B2/ja active Active
-
2019
- 2019-06-06 US US16/433,318 patent/US11406663B2/en active Active
-
2020
- 2020-01-10 AR ARP200100076A patent/AR117804A2/es unknown
-
2021
- 2021-09-01 JP JP2021142223A patent/JP7280318B2/ja active Active
-
2022
- 2022-07-11 US US17/861,413 patent/US20220347210A1/en not_active Abandoned
-
2025
- 2025-06-02 US US19/225,647 patent/US20250288608A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081395A1 (es) | Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y uso | |
| UY34903A (es) | ?minerales que contienen carbonato de calcio de superficie modificada y su uso?. | |
| IN2014DN08848A (enExample) | ||
| UY34144A (es) | ?proceso para la producción de carbonato de calcio precipitado, carbonato de calcio precipitado y sus usos | |
| CL2013000415A1 (es) | Proceso para la remineralizacion de agua que comprende inyectar dioxido de carbono gaseoso y una lechada al agua de alimentacion, en donde la lechada comprende carbonato de calcio micronizado; y uso de carbonato de calcio micronizado. | |
| CL2014001202A1 (es) | Uso de por lo menos un polimero de tipo peine anionicamente cargado contra el deposito en suspencion acuosa que comprende material que contiene carbonato de calcio; suspension acuosa; metodo de produccion de dicha suspension que reduce deposito; y uso de dicha suspension. | |
| CL2013000163A1 (es) | Proceso para la preparacion de material de carbonato de calcio que comprende proveer al menos un material que contenga carbonato de calcio, proveer al menos una sal de un acido graso c5-c28, tratar el material poniendolo en contacto con dicho acido graso y obtener dicho material tratado superficialmente; material de carbonato de calcio; y su uso en el control de material organico en un medio acuoso. | |
| MY170302A (en) | Process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate and its use | |
| ECSP13013036A (es) | Alfa glucosidasa ácida modificada con procesamiento acelerado | |
| CL2015001322A1 (es) | Sistemas y métodos de cartílago triturado. | |
| PH12013501894A1 (en) | Human tissue factor antibody and uses thereof | |
| AR087483A1 (es) | Carbonato de calcio con tratamiento de superficie para la union y biorremediacion de composiciones que contienen hidrocarburos | |
| AU341254S (en) | A toilet pan and cistern assembly | |
| AU341570S (en) | Vehicle emergency escape window handle | |
| AU343717S (en) | Sticking plaster used for medical purposes | |
| AU341246S (en) | A urinal | |
| CO6551745A2 (es) | Combinación de fármacos con teobromina y su uso en terapia | |
| MX2015009606A (es) | Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular. | |
| CL2013003727A1 (es) | Metodo para el tratamiento de piojos en peces que comprende la puesta en contacto del agua, alojando dichos peces, con cal particulada ( oxido de calcio y/o hidroxido de calcio); composicion que comprende cal particulada y sus usos. | |
| AU343718S (en) | Sticking plaster used for medical purposes | |
| CL2012002063A1 (es) | Proceso para hacer biodegradable un material polimerico sintetico, que comprende la adicion al material sintetico de una o mas levaduras; equipo para la implementacion de dicho proceso; y uso de levaduras. | |
| CL2012003645A1 (es) | Composicion farmaceutica de liberacion sostenida que comprende un compuesto derivado de metastina y un polimero de acido lactico; metodo de produccion; su uso para el tratamiento o prevencion del cancer. | |
| CA138824S (en) | Universal tank lever | |
| UA60845U (ru) | Способ лечения угрозы преждевременных родов на фоне тромбофилического состояния | |
| UA63274U (ru) | Способ консервации крови для кормления медицинских пиявок |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |